Cargando…

The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells

BACKGROUND: A phase I/II trial for glioblastoma with the oncolytic adenovirus Delta24-RGD was recently completed. Delta24-RGD conditionally replicates in cells with a disrupted retinoblastoma-pathway and enters cells via αvβ3/5 integrins. Glioblastomas are differentially sensitive to Delta24-RGD. HD...

Descripción completa

Detalles Bibliográficos
Autores principales: Berghauser Pont, Lotte M.E., Kleijn, Anne, Kloezeman, Jenneke J., van den Bossche, Wouter, Kaufmann, Johanna K., de Vrij, Jeroen, Leenstra, Sieger, Dirven, Clemens M.F., Lamfers, Martine L.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436250/
https://www.ncbi.nlm.nih.gov/pubmed/25993039
http://dx.doi.org/10.1371/journal.pone.0127058